Cancer Discovery

Article	Citations
Hallmarks of Cancer: New Dimensions	3414
Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak	1147
Therapeutic Targeting of the Tumor Microenvironment	671
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System	591
Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer	433
Liquid Biopsy: From Discovery to Clinical Application	417
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors	394
The Next Decade of Immune Checkpoint Therapy	372
Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level	312
Tuning the Antigen Density Requirement for CAR T-cell Activity	302
TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?	293
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation	244
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer	242
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab	236
Tumor-Infiltrating Natural Killer Cells	225
BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition	224
Artificial Intelligence in Cancer Research and Precision Medicine	223
The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells	216
Paradigms on Immunotherapy Combinations with Chemotherapy	204
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors	203
Modes of Regulated Cell Death in Cancer	194
Diffuse Glioma Heterogeneity and Its Therapeutic Implications	193
Fibroblast Heterogeneity in the Pancreatic Tumor Microenvironment	192
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers	189
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer	178

Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer	174
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade	171
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy	166
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited	161
Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes	154
Metabolic Codependencies in the Tumor Microenvironment	153
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial	153
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)	152
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC	151
HER2-Mediated Internalization of Cytotoxic Agents inERBB2Amplified or Mutant Lung Cancers	151
Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition	151
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib	149
Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation	147
Lower Airway Dysbiosis Affects Lung Cancer Progression	147
Metastasis-Initiating Cells and Ecosystems	145
Development of Immunotherapy Combination Strategies in Cancer	143
A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention	142
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors	142
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer	142
Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner	140
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis	139
Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer	138
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma	137
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response	136
Targeting Metabolic Plasticity and Flexibility Dynamics for Cancer Therapy	136
Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence	135
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers	133
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer	132
Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer	130
Targeting the p300/CBP Axis in Lethal Prostate Cancer	129
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer	128
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors HarboringFGF/FGFRAberrations: A Phase I Dose-Expansion Study	127
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures	125
Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma	123
The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis	120
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease	119
WNT as a Driver and Dependency in Cancer	117
St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem	116
The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets	115
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants	113
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies	111
Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability–High Gastric Cancer	110
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade	110
Mobocertinib (TAK-788): A Targeted Inhibitor ofEGFRExon 20 Insertion Mutants in Non–Small Cell Lung Cancer	110
Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer	107
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer	105
Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma	104
Selective Alanine Transporter Utilization Creates a Targetable Metabolic Niche in Pancreatic Cancer	104
Independent Drug Action in Combination Therapy: Implications for Precision Oncology	103
Mesenchymal Lineage Heterogeneity Underlies Nonredundant Functions of Pancreatic Cancer–Associated Fibroblasts	100

Tumor Microenvironment Is Critical for the Maintenance of Cellular States Found in Primary Glioblastomas	99
Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic	99
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study	99
Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance	98
Netrin G1 Promotes Pancreatic Tumorigenesis through Cancer-Associated Fibroblast–Driven Nutritional Support and Immunosuppression	97
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade	97
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab	95
Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy	95
Synthetic Lethality in Cancer Therapeutics: The Next Generation	95
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy	93
TargetingMETDysregulation in Cancer	93
Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers	93
Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes	92
Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy	91
Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing	91
A Procarcinogenic Colon Microbe Promotes Breast Tumorigenesis and Metastatic Progression and Concomitantly Activates Notch and β-Catenin Axes	91
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells	90
Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer	90
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer	90
A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy	90
Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy	89
KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition	89
A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota	88
The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution	88
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity	87
IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity	86
Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?	85
Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia	85
Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity	84
Epigenetic Switch–Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer	84
Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia	83
Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome	82
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial	82
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative	81
Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2	81
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma	80
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders	79
Tracking Cancer Evolution through the Disease Course	78
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers	78
Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity	77
Direct and Indirect Regulators of Epithelial–Mesenchymal Transition–Mediated Immunosuppression in Breast Carcinomas	77
CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies	77
A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era	75
Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors	75
Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia	75
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer	74
Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution	74
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors	74
A CRISPR/Cas9-Engineered ARID1A-Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation	74
NRF2: KEAPing Tumors Protected	73
An In Vivo Kras Allelic Series Reveals Distinct Phenotypes of Common Oncogenic Variants	72
The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies	72
Tumor Immunity and Immunotherapy for HPV-Related Cancers	72
CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade	72
EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma	72
IFNα Potentiates Anti–PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment	72
Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer	71
Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis	71
Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization	71
The Evolutionary Origins of Recurrent Pancreatic Cancer	71
Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis	69
Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing	69
Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety	68
Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression	68
Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers	68
The Complex Integration of T-cell Metabolism and Immunotherapy	68
Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations	68
Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade	68
Phase Separation Mediates NUP98 Fusion Oncoprotein Leukemic Transformation	66
Aggressive PDACs Show Hypomethylation of Repetitive Elements and the Execution of an Intrinsic IFN Program Linked to a Ductal Cell of Origin	65
Live-Cell Imaging Shows Uneven Segregation of Extrachromosomal DNA Elements and Transcriptionally Active Extrachromosomal DNA Hubs in Cancer	65
Redox Regulation in Cancer Cells during Metastasis	65
Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site	65
Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy	64
Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies	63
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements	63
Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System	63
CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory	62
Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation	62
Next-Generation CAR T-cell Therapies	61

Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer	60
Mechanisms of Resistance to KRASG12C-Targeted Therapy	60
Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC	60
Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation	58
Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer	58
Early Tumor–Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer	58
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo	58
PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity	57
Cell of Origin Influences Pancreatic Cancer Subtype	56
DietaryLactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy	56
SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies	55
Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches	55
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C	54
Global Regulation of the Histone Mark H3K36me2 Underlies Epithelial Plasticity and Metastatic Progression	54
TargetingEGFRExon 20 Insertions in Non–Small Cell Lung Cancer: Recent Advances and Clinical Updates	53
Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma	53
Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly EffectiveIn Vivowithout Systemic Immune Activation	53
Lineage Reversion Drives WNT Independence in Intestinal Cancer	53
Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity	53
Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy	52
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor	52
Macropinocytosis in Cancer-Associated Fibroblasts Is Dependent on CaMKK2/ARHGEF2 Signaling and Functions to Support Tumor and Stromal Cell Fitness	51
Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma	51
Combined Cohesin–RUNX1 Deficiency Synergistically Perturbs Chromatin Looping and Causes Myelodysplastic Syndromes	51
Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer	51
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients	50
Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung	50
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease	50
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions	49
Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy	48
Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing	48
African Ancestry–Associated Gene Expression Profiles in Triple-Negative Breast Cancer Underlie Altered Tumor Biology and Clinical Outcome in Women of African Descent	48
Cholesterol Auxotrophy as a Targetable Vulnerability in Clear Cell Renal Cell Carcinoma	48
DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells	47
Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade	47
ZFTA–RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma	47
NCOA4-Mediated Ferritinophagy Is a Pancreatic Cancer Dependency via Maintenance of Iron Bioavailability for Iron–Sulfur Cluster Proteins	47
Obesity-Dependent Adipokine Chemerin Suppresses Fatty Acid Oxidation to Confer Ferroptosis Resistance	46
Cancer in the Fourth Dimension: What Is the Impact of Circadian Disruption?	46
Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity	45
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain	45
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown	45
FGFR2Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma	45
PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN	45
Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages	45
Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer	44
MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression	44
Bacterial-Driven Inflammation and Mutant BRAF Expression Combine to Promote Murine Colon Tumorigenesis That Is Sensitive to Immune Checkpoint Therapy	43
The Cancer Microbiome: Recent Highlights and Knowledge Gaps	43
CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells	43
Discovery and Features of an Alkylating Signature in Colorectal Cancer	43
H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone	43
The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2	43
Sex-BiasedZRSR2Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis	43
Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia	43
Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer	42
Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis	42
Cancer Induces a Stress Ileopathy Depending on β-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis	41
RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease	41
Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation	41
Splicing Patterns in SF3B1-Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neoepitopes	41
Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors	41
Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer	41
Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma	40
Golgi Acidification by NHE7 Regulates Cytosolic pH Homeostasis in Pancreatic Cancer Cells	40
Discovery of Candidate DNA Methylation Cancer Driver Genes	40
Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis	40
Human Colon Cancer–Derived Clostridioides difficile Strains Drive Colonic Tumorigenesis in Mice	40
Detecting Liver Cancer Using Cell-Free DNA Fragmentomes	40
The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes	40
C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan	40
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors	39
Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death	39
Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia	39
Simultaneous Inhibition of LSD1 and TGFβ Enables Eradication of Poorly Immunogenic Tumors with Anti–PD-1 Treatment	39
Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL	39
Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas	38
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant inPIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers	38
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy	38
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC	38
A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS–Driven Lung Cancer	37
Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis	37
KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs	37
Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy	37
Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD+ to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells	37
Classification ofKRAS-Activating Mutations and the Implications for Therapeutic Intervention	37
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer	37
Decoding Cancer Biology One Cell at a Time	37
Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia	37
Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy	37
Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1	37
Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis	36
AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway–Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B	36
Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade	36
CD4 T Cell–Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair–Deficient Tumors	36